Immupharma (IMM) RNS Announcements

Add to Alert list
Date Time Source Announcement
23 Sep 2011 09:34 AM
RNS
Notification of Interim Results
12 Jul 2011 02:47 PM
RNS
Notification of Major Interest in Shares
19 May 2011 11:19 AM
RNS
Result of Annual General Meeting
05 May 2011 07:00 AM
RNS
IPP-204106 paper published
26 Apr 2011 04:38 PM
RNS
Annual Report and Accounts & Notice of AGM
05 Apr 2011 07:00 AM
RNS
Preliminary Results
30 Mar 2011 07:00 AM
RNS
Notification of Preliminary Results
21 Feb 2011 07:00 AM
RNS
Update on progress of Phase I/IIa Clinical Trial
19 Oct 2010 01:08 PM
RNS
Update on Phase IIa Clinical
11 Oct 2010 02:30 PM
RNS
Notification of major interes
11 Oct 2010 02:30 PM
RNS
Additional Listing and Total
30 Sep 2010 07:00 AM
RNS
Interim Results
28 Sep 2010 10:18 AM
RNS
Notification of Interim Resul
28 Jun 2010 07:00 AM
RNS
Presentation at the Internati
23 Jun 2010 07:40 AM
RNS
Replacement of Development re
23 Jun 2010 07:00 AM
RNS
Cephalon initiates critical s
17 Jun 2010 12:02 PM
RNS
Result of AGM
10 Jun 2010 10:55 AM
RNS
Annual Report and Accounts
19 May 2010 07:01 AM
RNS
Initiation Of Phase I/IIA Stu
19 May 2010 07:00 AM
RNS
Preliminary Results
08 Apr 2010 09:26 AM
RNS
Best Drug Development Company
05 Jan 2010 03:00 PM
RNS
Additional Listing
05 Jan 2010 07:00 AM
RNS
ING take 4% stake in ImmuPhar
03 Dec 2009 07:00 AM
RNS
R&D Symposium at the CNRS in
19 Nov 2009 07:00 AM
RNS
Positive Final Lupuzor Trial
19 Oct 2009 10:31 AM
RNS
'Best Technology 2009' Award
09 Oct 2009 10:14 AM
RNS
Appointment of Joint Broker
29 Sep 2009 07:00 AM
RNS
Interim Results
21 Sep 2009 09:55 AM
RNS
8th Annual Bio Investor Forum
17 Sep 2009 07:00 AM
RNS
JMP Healthcare Focus Conferen
24 Jul 2009 12:12 PM
RNS
Result of AGM
23 Jul 2009 04:17 PM
RNS
Directors' Dealings
30 Jun 2009 07:00 AM
RNS
Annual Report and Accounts
24 Jun 2009 07:00 AM
RNS
Preliminary Results
17 Jun 2009 07:00 AM
RNS
Piper Jaffray Europe Conferen
23 Mar 2009 07:00 AM
RNS
Directors' Dealings
04 Feb 2009 12:32 PM
RNS
Share Options
02 Feb 2009 02:33 PM
RNS
Cephalon license exercise
30 Jan 2009 07:00 AM
RNS
Successful trial results
22 Dec 2008 12:00 PM
RNS
further instalment of grant
25 Nov 2008 07:00 AM
RNS
Option Agreement with Cephalo
12 Nov 2008 07:00 AM
RNS
Grant Award
21 Oct 2008 09:31 AM
RNS
Patents Granted
17 Oct 2008 04:22 PM
RNS
Additional Listing and Total
25 Sep 2008 07:00 AM
RNS
Interim Results
05 Aug 2008 03:44 PM
RNS
AGM Result
10 Jul 2008 07:00 AM
RNS
Second Placing
02 Jul 2008 07:30 AM
RNS
Toxicology study
02 Jul 2008 07:00 AM
RNS
Fund Raising
30 Jun 2008 03:00 PM
RNS
Annual Report and Accounts

ImmuPharma is a pharma company headquartered in London with its research R&D team, ImmuPharma Biotech, based in France. 

ImmuPharma listed on AIM under the ticker IMM. 

IMM research strategy is based on two strategic axes: research based on external collaboration aimed at discovering new active ingredients, which has led to the development of our most advanced project in terms of clinical development: P140 an active peptide against the auto-immune disease, Lupus SLE and internal research based on the use of molecular programming technologies, which has notably led to the development of the BioAMB and BioCIN projects.

IMM share price listed in London at 1,190p in 2000. 

UK 100

Latest directors dealings